Navigation Links
Des défenseurs d'un traitement contestent un brevet pour un nouveau médicament contre l'hépatite C
Date:11/24/2013

C vivant dans des pays à revenus faibles et moyens, un tel prix rendra ce traitement inaccessible pour la plupart des patients.

« Sans une concurrence des génériques en provenance de l'Inde, il faudra attendre trop longtemps avant que les entreprises détentrices de brevet abaissent leurs prix », selon Tahir Amin, directeur de l'Initiative for Medicines, Access & Knowledge. « Ce médicament est une variante de composés connus, et le droit indien ne permettra pas à une entreprise de réaliser des milliards de dollars grâce à lui ».

Qualifiée de « bombe virale à retardement » par l'Organisation mondiale de la santé, hépatite C chronique touche, selon les estimations, 170 millions de personnes dans le monde, dont 12 millions en Inde. Cette maladie infecte près de 4 millions de personnes chaque année et est à l'origine de 350 000 décès tous les ans.

Open Society Foundations aide les groupes de patients et les défenseurs de traitements à faciliter l'accès au traitement de l'hépatite C dans de nombreux pays à moyens revenus, dont la Géorgie, l'Ukraine, le Vietnam, la Thaïlande, le Brésil et la Russie, où leur prix rend inabordables les traitements mêmes actuels contre l'hépatite C.

Open Society Foundations œuvre en faveur de démocraties dynamiques et tolérantes dont les gouvernements sont responsables envers leurs citoyens. Collaborant avec les communautés locales dans plus de 100 pays, Open Society Foundations encourage la justice et les droits de l'homme, la liberté d'expression et l'accès à la santé publique et à l'éducation.

L'Initiative for Medicines, Access, & Knowledge (I-MA
'/>"/>

SOURCE Open Society Foundations
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
2. Traitement du cancer primaire du foie : létude SARAH désormais accessible aux patients concernés sur lensemble du territoire français
3. Diagnostic et traitement du cancer : une encyclopédie gratuite en ligne
4. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
5. Puritan Medical Products obtient deux nouveaux brevets en Australie pour ses écouvillons floqués
6. Un nouveau test moléculaire pour le dépistage pré-chirurgical détecte les souches MRSA récemment découvertes
7. MNX nomme un nouveau membre à son conseil dadministration, la société vise à accélérer sa croissance dans la logistique pour les domaines pharmaceutique et des essais cliniques
8. Après son lancement réussiaux États-Unis, le nouveau Simbionix U/S Mentor va être présenté pour la première fois en Europe
9. Nouveau Life Pharmaceuticals (NOUV) Releases Calcium & Vitamin D for Strong Bones
10. Nouveau Life Offers Potential Distributors Online Access to Company and Contract
11. Nouveau Life Pharmaceuticals (NOUV) Releases Krill Oil to Support Healthy Cholesterol Levels and Reduce Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... GLASGOW, Scotland , July 24, 2014 Cancer ... will gain access to state-of-the-art cancer treatment closer to home ... next year. Varian Medical Systems (NYSE: ... and an order was placed in June for four TrueBeam™ ... TrueBeam systems, which offer fast and efficient radiotherapy and radiosurgery ...
(Date:7/24/2014)... July 24, 2014 Second Quarter ... President and Chief Executive Officer effective September 2, 2014 ... $20.4 million , BioGlue ® revenues grew ... ® revenues grew 22 percent year-over-year to $1.1 ... 20 percent year-over-year to $1.7 million , Tissue ...
(Date:7/24/2014)... Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: ... it has filed a detailed complaint with the ... (NYSE: AGN ) apparent attempts to ... price of Valeant,s common shares by continuing to ... despite Valeant,s public statements correcting this misinformation. A ...
Breaking Medicine Technology:Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6
... YORK, Feb. 15, 2012 Delcath Systems, Inc. (NASDAQ: ... ( Instituto Europeo di Oncologia – IEO) introduced ... a Feb. 15 press conference and discussed the status ... CHEMOSAT is a critical new treatment option for patients ...
... ERT (NASDAQ: ERT ) announced today that it ... year 2011 Monday, February 27, after the market closes. After ... 5:00 PM ET that day. For the conference ... United States or 1-412-858-4600 when calling internationally. There will be ...
Cached Medicine Technology:Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 2Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 3Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 4ERT to Report Fourth Quarter and Full Year 2011 Operating Results 2
(Date:7/24/2014)... 24, 2014 Pools and beaches are the ... can be dangerous, especially for small children, so Amica ... , According to the Centers for Disease Control and Prevention, ... at risk for water-related injuries and deaths. It’s important to ... water, so Amica is offering the following tips from the ...
(Date:7/24/2014)... SHAWNEE, Kan. (PRWEB) July 24, 2014 ... announces that it has achieved certification for ... as tested and verified by the DoD Information ... Acuo Vendor Neutral Archive, identified within the DoD ... the Authority to Operate designation from the U.S. ...
(Date:7/24/2014)... new study led by the Translational Genomics Research Institute ... and the immune system during HIV infection. , Currently, ... infect others based on their blood viral load. ... their semen despite having low levels in their blood. ... virus can be found in different parts of the ...
(Date:7/24/2014)... Atlanta, GA (PRWEB) July 24, 2014 ... Act on Tuesday, President Obama cited the Atlanta ... 35 model programs from across the country ( ... training as an essential pillar of U.S. economic ... replicated nationally. , “This recognition from President Obama ...
(Date:7/24/2014)... that it is possible to predict long-term cancer risk from ... same exposure. The findings, which currently appear in the journal ... simpler and cheaper tests to screen chemicals for their potential ... in incidence of and mortality from cancer, about 40 percent ... lifetime, and around 20 percent will die of it. Currently ...
Breaking Medicine News(10 mins):Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Researchers discover new way to determine cancer risk of chemicals 2
... fibronectin can predict whether a pregnant woman is at ... risk for pre-term births are women with previous pre-term ... suffer from diabetes and/or hypertension. The current approach for ... is the use of a clinical scoring system, ...
... technology born of genetic ,engineering, and known as naked ... such as multiple ,sclerosis and rheumatoid arthritis. , ... In multiple sclerosis (MS) and ,rheumatoid arthritis (RA), the ... myelin sheath of nerves falls ,victim, while in RA, ...
... requiring heart bypass ,speeds recovery in children undergoing ... clinical trial published in The Lancet., , ... underwent long and difficult surgeries. Following trauma or ... concentrations plummet. Many experts thought this was an ...
... derivatives from garlic may potentially play a role in ... review published in a recent issue of Nutrition in ... effect of garlic on risk factors for heart disease. ... LDL ("bad") ,cholesterol and blood pressure. It may also ...
... painkillers to ease the agony of terminally ill patients ... the practice, comparing it to euthanasia, but doctors at ... doses of drugs such as morphine live just as ... research published in The Lancet medical journal, they compared ...
... Antibiotcs seem to treat or prevent the symptoms of autism ... is affected by autism. Currently there are no treatments for ... found that a subset of patients with autism who experience ... by antibiotic vancomycin. ,Interestingly the study was done ...
Cached Medicine News:
Collars can be attach to any Pulse aprons....
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
... necessary, the Two-Piece should be your ... comfort through more efficient distribution of ... vest comes with shoulder pads and ... well as an attached belt to ...
Quick Release buckle apron is user friendly with large support straps crisscrossing the back allowing proper placement of the belt at your waist....
Medicine Products: